Vnitr Lek 2013, 59(7):618-621

Relationship of bilirubin to diseases caused by increased oxidative stress

L. Vítek1,2
1 IV. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Aleš Žák, DrSc.
2 Ústav lékařské biochemie a laboratorní diagnostiky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Tomáš Zima, DrSc., MBA

Oxidative stress contributes importantly to pathogenesis of numerous civilization diseases, including cardiovascular diseases, cancer, as well as autoimmune and neurodegenerative conditions. Bilirubin is the major product of the heme catabolic pathway in the intravascular compartment. For long time, bilirubin was considered to be only a waste product, however, recent data from the last 2 decades have proved its important antioxidant properties, which contributes to defense against increased oxidative stress. Numerous experimental as well as clinical studies have demonstrated association between low bilirubin concentrations and cardiovascular diseases, diabetes, certain cancers, autoimunne diseases, such as lupus erythematodes, or rheumatoid arthritis or neurological-psychiatric disorders, such as schizofrenia. On the other hand, subjects with mildly elevated blood bilirubin levels, typical for Gilbert syndrome, have decreased risk of these diseases.

Keywords: bilirubin; oxidative stress; antioxidant; Gilbert syndrome

Received: May 6, 2013; Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítek L. Relationship of bilirubin to diseases caused by increased oxidative stress. Vnitr Lek. 2013;59(7):618-621.
Download citation

References

  1. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007; 43: 1-57. Go to original source... Go to PubMed...
  2. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008; 198: 1-11. Go to original source... Go to PubMed...
  3. Vitek L, Ostrow JD. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des 2009; 15: 2869-2883. Go to original source... Go to PubMed...
  4. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010; 56: 1535-1543. Go to original source... Go to PubMed...
  5. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003; 228: 568-571. Go to original source...
  6. Bernard K, Ritzel G, Steiner KU. Über eine biologische bedeutung der gallenfarbstoffe: Bilirubin und biliverdin als antioxydantien für das vitamin A und die essentiellen Fettsäuren. Helv Chim Acta 1954; 37: 306-313. Go to original source...
  7. Stocker R, Yamamoto Y, McDonagh AF et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046. Go to original source... Go to PubMed...
  8. Wu TW, Fung KP, Yang CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci 1994; 54: 477-481. Go to original source...
  9. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988; 85: 9748-9752. Go to original source... Go to PubMed...
  10. Mazzone GL, Rigato I, Ostrow JD et al. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 2009; 386: 338-344. Go to original source... Go to PubMed...
  11. Tapan S, Dogru T, Tasci I et al. Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: a link to protection against atherosclerosis? Clin Biochem 2009; 42: 791-795. Go to original source... Go to PubMed...
  12. Basiglio CL, Arriaga SM, Pelusa F et al. Complement activation and disease: protective effects of hyperbilirubinaemia. Clin Sci (Lond) 2010; 118: 99-113. Go to original source... Go to PubMed...
  13. Hwang HJ, Lee SW, Kim SH. Relationship between bilirubin and C-reactive protein. Clin Chem Lab Med 2011; 49: 1823-1828. Go to original source... Go to PubMed...
  14. Yoshino S, Hamasaki S, Ishida S et al. Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. J Atheroscler Thromb 2011; 18: 403-412. Go to original source... Go to PubMed...
  15. Vitek L, Malikova I, Kvasnicka J et al. Relationship between serum bilirubin and markers of inflammation and oxidative stress. J Gastroenterol Hepatol 2007; 22: A235. Go to original source... Go to PubMed...
  16. Rocuts F, Zhang X, Yan J et al. Bilirubin promotes de novo generation of T regulatory cells. Cell Transplant 2010; 19: 443-451. Go to original source... Go to PubMed...
  17. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994; 40: 18-23. Go to original source...
  18. Vitek L, Jirsa M, Brodanova M et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002; 160: 449-456. Go to original source... Go to PubMed...
  19. Vitek L, Novotny L, Sperl M et al. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 2006; 21: 408-414. Go to original source... Go to PubMed...
  20. Ajja R, Lee DC, Sui X et al. Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol 2011; 108: 1438-1442. Go to original source... Go to PubMed...
  21. Ko GT, Chan JC, Woo J et al. Serum bilirubin and cardiovascular risk factors in a Chinese population. J Cardiovasc Risk 1996; 3: 459-463. Go to original source... Go to PubMed...
  22. Inoguchi T, Sasaki S, Kobayashi K et al. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 2007; 298: 1398-1400. Go to original source... Go to PubMed...
  23. Fukui M, Tanaka M, Yamazaki M et al. Low serum bilirubin concentration in haemodialysis patients with Type 2 diabetes. Diabet Med 2011; 28: 96-99. Go to original source... Go to PubMed...
  24. Cheriyath P, Gorrepati VS, Peters I et al. High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES data from 1999-2006. J Clin Med Res 2010; 2: 201-206. Go to original source... Go to PubMed...
  25. Lin LY, Kuo HK, Hwang JJ et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009; 203: 563-568. Go to original source... Go to PubMed...
  26. Wu Y, Li M, Xu M et al. Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 2011; 3: 217-224. Go to original source... Go to PubMed...
  27. Kwon KM, Kam JH, Kim MY et al. Inverse association between total bilirubin and metabolic syndrome in rural korean women. J Womens Health 2011; 20: 963-969. Go to original source... Go to PubMed...
  28. Choi SH, Yun KE, Choi HJ. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr Metab Cardiovasc Dis 2013; 23: 31-37. Go to original source... Go to PubMed...
  29. Bhuiyan AR, Srinivasan SR, Chen W et al. Association of serum bilirubin with pulsatile arterial function in asymptomatic young adults: the Bogalusa Heart Study. Metabolism 2008; 57: 612-616. Go to original source... Go to PubMed...
  30. Andersson C, Weeke P, Fosbøl EL et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 2009; 58: 1109-1115. Go to original source... Go to PubMed...
  31. Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the US population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40: 827-835. Go to original source... Go to PubMed...
  32. Jiraskova A, Novotny J, Novotny L et al. Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer. Int J Cancer 2012; 131: 1549-1555. Go to original source... Go to PubMed...
  33. Temme EH, Zhang J, Schouten EG et al. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 2001; 12: 887-894. Go to original source... Go to PubMed...
  34. Vitek L, Muchova L, Jancova E et al. Association of systemic lupus erythematosus with low serum bilirubin levels. Scand J Rheumatol 2010; 39: 480-484. Go to original source... Go to PubMed...
  35. Ilzecka J, Stelmasiak Z. Serum bilirubin concentration in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2003; 105: 237-240. Go to original source... Go to PubMed...
  36. Vitek L, Novotna M, Lenicek M et al. Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Res 2010; 178: 449-450. Go to original source... Go to PubMed...
  37. McCarty MF. "Iatrogenic Gilbert syndrome'' - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007; 69: 974-994. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.